IDS · Western blot design guide

IDS Western Blot Planning Guide

Plan an IDS Western blot around the catalog-observed 61.9 kDa band, image-backed PA1917 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for IDS (IDS): expected band 61.9 kDa, antibody PA1917, and guide-derived SDS-PAGE protocol steps
IDS Western blot protocol sheet — expected band 61.9 kDa, antibody PA1917, controls and PMC citations. Open the full IDS WB guide →

IDS Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 61.9 kDa
Observed band Not reported — verify product WB image
Gel 12-15%
Positive control ⓘ Cervix
Negative control ⓘ Soft tissue
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 61.9 kDa
ⓘ Localization Lysosome
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human
Section 1

Real Curated IDS Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateAdrenal gland
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, standard transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryPA1917 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected IDS Western Blot Band Size?

Use the product-observed 61.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
61.9 kDaMatches the authoritative product WB observation.
61.9 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected IDS appearancePlan around 61.9 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band61.9 kDa; use this as the primary experimental expectation.
Calculated mass61.9 kDa from UniProt P22304; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with PA1917.
Why is my band missing or off?
SituationLikely causeNext action
61.9 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for IDS Western blot

🧪Use Cervix as the first positive-control candidate and Soft tissue as the HPA Not detected negative candidate.
Positive control: Cervix (High)
Negative control: Soft tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for IDS

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Cervix Reported tissue cells High Protein (HPA) HPA →
Colon Reported tissue cells High Protein (HPA) HPA →
Adrenal gland Reported tissue cells High Protein (HPA) HPA →
Appendix Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Soft tissue Reported tissue cells Not detected Protein (HPA) HPA →
Adipose tissue Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced IDS Western Blot Tips

Deeper troubleshooting and optimisation questions for IDS, answered from its protein features.

Which band should guide the blot?
Use 61.9 kDa, the observation attached to the authoritative PA1917 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 61.9 kDa expectation.
Which positive control should I start with?
Start with Cervix, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Soft tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for IDS Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PA1917 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

IDS Western Blot Reagents

Human-reactive IDS Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for IDS using PA1917; observed band 61.9 kDa
Anti-Iduronate 2 sulfatase/IDS Antibody Picoband®
Cat # PA1917

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P22304
  2. Human Protein Atlas — IDS
  3. PA1917 product record
  4. PMC13370725 — RNF13 is a previously undescribed interactor of iduronate 2-sulfatase that modifies its glycosylation and maturation (The FEBS journal, 2026)
  5. PMC6057917 — Shutdown of ER-associated degradation pathway rescues functions of mutant iduronate 2-sulfatase linked to mucopolysaccharidosis type II (Cell death & disease, 2018)